Healt

ASX 200 Today Pro Medicus (ASX:PME) Positioned Within the Shifting ASX Stock Market

September 07, 2025 08:11 PM AEST| By Sam

Highlights,Pro Medicus gains attention in the ASX stock market due to insider activity,Positioned among ASX Healthcare stocks within the S&P/ASX 200 index,Importance of Pro Medicus within the wider scope of ASX 200 stocks and ASX 200 Companies,Releva...

All ords index EZZ Life Science Holdings (ASX:EZZ) Faces Earnings Quality Challenges

September 06, 2025 03:42 AM AEST| By Sam

Highlights,EZZ Life Science Holdings reported weak earnings quality, with free cash flow not aligning with accounting,Dilution through new share issuance impacted per-share earnings outcomes,Company is part of the All ords index, increasing its visib...

Healius’s (ASX: HLS) 2025 Special Dividend: A Historic Yield Event for Market Participants

September 05, 2025 05:42 PM AEST| By Team Kalkine Media

Dividend yield — a key measure for income-oriented market participants — expresses the cash paid to shareholders relative to the market price of a company’s shares. For steady payers, yields usually mirror sustainable earnings capacity. When yields c...

PheCheck and FebriDx Programs Advance with Global Backing Beyond the ASX 200

September 05, 2025 01:15 PM AEST| By Sam

Lumos Diagnostics (ASX:LDX) strengthens Aptatek and BARDA collaborations to advance PheCheck™ and FebriDx®, highlighting innovation in healthcare diagnostics beyond major ASX indices.

Race Oncology Expands Global RC220 Trial Sites as ASX 200 Sector Watches Oncology Developments

September 05, 2025 12:01 PM AEST| By Sam

Race Oncology (ASX:RAC) advances its RC220 trial across Australia, Hong Kong, and South Korea, marking a significant oncology milestone within the ASX healthcare and biotech landscape.

ASX 200 Today Evaluating Ramsay Health Care (ASX:RHC) Amidst Soft Earnings and Future Prospects

September 04, 2025 09:05 PM AEST| By Sam

Highlights,Ramsay Health Care reported softer-than-expected earnings, impacted by unusual expenses.,Underlying operational performance shows resilience and for recovery.,Analysis suggests the company’s earnings may improve if one-off costs do not rec...

Unlocking Share Price Insights and its Role in the ASX 200 Landscape

September 04, 2025 08:30 PM AEST| By Team Kalkine Media

Explore CSL Ltd (ASX:CSL) in depth—its healthcare leadership, financial strength, and long-term growth within the ASX 200, with insights into its market role and outlook.

Patrys Limited Expands Capital Base with ASX Quotation All Ordinaries

September 04, 2025 04:05 PM AEST| By Sam

Highlights,Patrys Limited (ASX:PAB) announces quotation of new fully paid ordinary securities on the ASX,The update follows a capital initiative first disclosed earlier in the year,Market stakeholders may see this as a shift in the company’s capital...

Breakthrough for 4DMedical: Medicare Approval Sets Stage for Wider CT:VQ Adoption in US Healthcare

September 04, 2025 12:33 PM AEST| By Team Kalkine Media

4DMedical (ASX:4DX) gains US Medicare approval for its CT:VQ imaging platform, securing both regulatory and financial clarity to drive expansion in respiratory diagnostics across healthcare networks.

How BPH Global (ASX:BP8) Explores a New Frontier Beyond Traditional Sectors

September 04, 2025 12:29 PM AEST| By Team Kalkine Media

BPH Global (ASX:BP8) explores seaweed’s potential for critical mineral recovery, partnering with Marchwood Labs to advance sustainable solutions for rare earth demand and global resource challenges.

4DMedical Gains US Reimbursement Approval for CT:VQ Imaging as ASX 200 Healthcare Innovation Advances

September 04, 2025 12:06 PM AEST| By Team Kalkine Media

4DMedical (ASX:4DX) secures US reimbursement approval for its CT:VQ lung imaging software, aligning regulatory clearance with commercial rollout to advance respiratory diagnostics across American healthcare networks.

Cochlear (ASX:COH) in Spotlight: Key Insights Driving ASX 200 Growth

September 04, 2025 10:23 AM AEST| By Team Kalkine Media

Discover how Cochlear (ASX:COH), a global leader in hearing solutions, strengthens its position in the ASX 200 with strong fundamentals and innovative healthcare advancements.

Cochlear (ASX:COH) delivers consistent five-year returns ASX 100

September 03, 2025 06:25 PM AEST| By Team Kalkine Media

Highlights,Cochlear's performance aligns with strong earnings progression over recent years,Company continues to maintain consistency across dividends and share value,ASX 100 stock shows steady sentiment reflected in long-term shareholder returns,Coc...

Integral Diagnostics (ASX:IDX) Earnings Show Mixed Signals Amid Dilution ASX 300 Watch

September 03, 2025 06:17 PM AEST| By Team Kalkine Media

Highlights,Integral Diagnostics (ASX:IDX) reports earnings influenced by a sharp increase in issued shares,Earnings per share diluted significantly due to expanded capital base,One-off items played a major role in shaping the net profit outcome,Integ...

ASX 200 Botanix Pharmaceuticals (ASX:BOT) Sees Ownership Strain Amid Market Dip

September 03, 2025 04:29 PM AEST| By Team Kalkine Media

Highlights,Botanix Pharmaceuticals’ ownership is dominated by individual shareholders with a broad spread,Institutional investors have significant influence but not majority control,Insider ownership reflects leadership involvement in equity holding,...

4DMedical (ASX: 4DX) Surges on U.S. Reimbursement Breakthrough ASX 300

September 03, 2025 04:22 PM AEST| By Team Kalkine Media

Highlights,4DMedical receives U.S. reimbursement approval for its lung imaging software CT:VQ.,Medicare backing confirms both regulatory and commercial viability of the company’s technology.,New milestone could accelerate hospital adoption and broade...

Argenica Therapeutics (ASX:AGN) Faces Clinical Setback Can Subgroup Results Provide Direction?

September 03, 2025 02:36 PM AEST| By Team Kalkine Media

Highlights,Argenica Therapeutics reported topline data from its stroke treatment trial, showing no broad efficacy.,Subgroup findings revealed a signal of reduced brain tissue damage in patients with slower collateral blood flow.,Market sentiment shif...